Información del artículo
Abstract
There exist many skin-directed and systemic immunomodulating or cytotoxic treatment options for primary cutaneous T- and B-cell lymphomas. However, especially in advanced stages conventional therapies only end in a transient remission without curative results unable to prolong overall survival. Over the last twenty years the high need of new therapeutic strategies resulted in the development of emerging drugs targeting more tumor specific, like monoclonal antibodies, histone-deacetylase inhibitors, proteasome inhibitors, or fusion proteins.
This article aims to discuss the conventional treatment modalities as well as new therapeutic strategies, which passed already through clinical trials showing promising results in the treatment of primary cutaneous lymphomas.
Key words:
primary cutaneous lymphoma
conventional therapy
emerging drugs
monoclonal antibody
HDACI
chemotherapy
Resumen
Existen varias opciones terapéuticas dirigidas a la piel y sistémicas, inmunomoduladoras o citotóxicas, para los linfomas cutáneos primarios de células B y T. No obstante, las terapias convencionales sólo consiguen una remisión transitoria sin resultados curativos, incapaces, por tanto, de prolongar la supervivencia global, especialmente en fases avanzadas. En los últimos 20 años, debido a la creciente necesidad de nuevas estrategias terapéuticas, se han desarrollado fármacos con dianas tumorales más específicas, como los anticuerpos monoclonales, los inhibidores de la histona deacetilasa, los inhibidores del proteosoma o las proteínas de fusión.
Este trabajo tiene por objetivo discutir las modalidades terapéuticas convencionales, así como las nuevas estrategias terapéuticas que ya han mostrado resultados prometedores para el tratamiento de los linfomas cutáneos primarios en ensayos clínicos.
Palabras clave:
linfoma cutáneo primario
terapia convencional
fármacos emergentes
anticuerpo monoclonal
inhibidores de la histona deacetilasa
quimioterapia
El Texto completo está disponible en PDF
References
[1.]
E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, R. Kurzrock.
Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis.
Blood, 92 (1998), pp. 1150-1159
[2.]
R.S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, T.M. Kuzel.
Primary cutaneous T-cell lymphoma: review and current concepts.
J Clin Oncol, 18 (2000), pp. 2908-2925
[3.]
M. Girardi, P.W. Heald, L.D. Wilson.
The pathogenesis of mycosis fungoides.
N Engl J Med, 350 (2004), pp. 1978-1988
[4.]
M. Paulli, E. Berti.
Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
Haematologica, 89 (2004), pp. 1372-1388
[5.]
R. Willemze, R.C. Beljaards.
Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
J Am Acad Dermatol, 28 (1993), pp. 973-980
[6.]
R. Willemze, E.S. Jaffe, G. Burg, L. Cerroni, E. Berti, S.H. Swerdlow, et al.
WHO-EORTC classification for cutaneous lymphomas.
Blood, 105 (2005), pp. 3768-3785
[7.]
E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, et al.
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
Blood, 110 (2007), pp. 1713-1722
[8.]
V.D. Criscione, M.A. Weinstock.
Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.
Arch Dermatol, 143 (2007), pp. 854-895
[9.]
Y.H. Kim, R.A. Jensen, G.L. Watanabe, A. Varghese, R.T. Hoppe.
Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Arch Dermatol, 132 (1996), pp. 1309-1313
[10.]
H.L. Liu, R.T. Hoppe, S. Kohler, J.D. Harvell, S. Reddy, Y.H. Kim.
CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
J Am Acad Dermatol, 49 (2003), pp. 1049-1058
[11.]
L. Cerroni, S. Signoretti, G. Höfler, G. Annessi, B. Pütz, E. Lackinger, et al.
Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma.
Am J Surg Pathol, 21 (1997), pp. 1307-1315
[12.]
J.J. Hoefnagel, M.H. Vermeer, P.M. Jansen, G.J. Fleuren, C.J. Meijer, R. Willemze.
Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance.
Br J Dermatol, 149 (2003), pp. 1183-1191
[13.]
F.J. Kaye, P.A. Bunn Jr, S.M. Steinberg, J.L. Stocker, D.C. Ihde, A.B. Fischmann, et al.
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.
N Engl J Med, 321 (1998), pp. 1784-1790
[14.]
K.J. Neelis, E.C. Schimmel, M.H. Vermeer, N.J. Senff, R. Willemze, E.M. Noordijk.
Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.
Int J Radiat Oncol Biol Phys, 74 (2009), pp. 154-158
[15.]
F. Trautinger, R. Knobler, R. Willemze, K. Peris, R. Stadler, L. Laroche, et al.
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Eur J Cancer, 42 (2006), pp. 1014-1030
[16.]
H.S. Zackheim, M. Kashani-Sabet, S. Amin.
Topical corticosteroids for mycosis fungoides. Experience in 79 patients.
Arch Dermatol, 134 (1998), pp. 949-954
[17.]
E.J. Kim, S. Hess, S.K. Richardson, S. Newton, L.C. Showe, B.M. Benoit, et al.
Immunopathogenesis and therapy of cutaneous T cell lymphoma.
J Clin Invest, 115 (2005), pp. 798-812
[18.]
D.L. Ramsay, P.S. Halperin, A. Zeleniuch-Jacquotte.
Topical mechlorethamine therapy for early stage mycosis fungoides.
J Am Acad Dermatol, 19 (1988), pp. 684-691
[19.]
Y.H. Kim, G. Martínez, A. Varghese, R.T. Hoppe.
Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Arch Dermatol, 139 (2003), pp. 165-173
[20.]
H.S. Zackheim.
Topical carmustine (BCNU) in the treatment of mycosis fungoides.
Dermatol Ther, 16 (2003), pp. 299-302
[21.]
S.J. Whittaker, J.R. Marsden, M. Spittle, R. Russell Jones.
Joint British Association of Dermatologists and and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.
Br J Dermatol, 149 (2003), pp. 1095-1107
[22.]
D.L. Ramsay, K.M. Lish, C.B. Yalowitz, N.A. Soter.
Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma.
Arch Dermatol, 128 (1992), pp. 931-933
[23.]
P.V. Diederen, H. van Weelden, C.J. Sanders, J. Toonstra, W.A. van Vloten.
Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retroperspective study.
J Am Acad Dermatol, 48 (2003), pp. 215-219
[24.]
C. Querfeld, S.T. Rosen, T.M. Kuzel, K.A. Kirby, H.H. Roenigk Jr, B.M. Prinz, et al.
Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Arch Dermatol, 141 (2005), pp. 305-311
[25.]
E.A. Abel, E. Sendagorta, R.T. Hoppe, C.H. Hu.
PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study.
Arch Dermatol, 123 (1987), pp. 897-901
[26.]
F.J. Child, T.J. Mitchell, S.J. Whittaker, J.J. Scarisbrick, P.T. Seed, R. Russell-Jones.
A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.
Clin Exp Dermatol, 29 (2004), pp. 231-236
[27.]
J.J. Scarisbrick, P. Taylor, U. Holtick, Y. Makar, K. Douglas, G. Berlin, et al.
U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.
Br J Dermatol, 158 (2008), pp. 659-678
[28.]
K.E. McKenna, S. Whittaker, L.E. Rhodes, P. Taylor, J. Lloyd, S. Ibbotson, et al.
Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.
Br J Dermatol, 154 (2006), pp. 7-20
[29.]
R. Edelson, C. Berger, F. Gasparro, B. Jegasothy, P. Heald, B. Wintroub, et al.
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.
N Engl J Med, 316 (1987), pp. 297-303
[30.]
R. Knobler, C. Jantschitsch.
Extracorporeal photoimmunochemotherapy in cutaneous T-cell lymphoma.
Transfus Apheresis Sci, 28 (2003), pp. 81-89
[31.]
B.D. Smith, L.D. Wilson.
Management of mycosis fungoides. Treatment: part 2.
Oncology, 17 (2003), pp. 1419-1428
[32.]
G.W. Jones, B.M. Kacinski, L.D. Wilson, R. Willemze, M. Spittle, G. Hohenberg, et al.
Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group.
J Am Acad Dermatol, 47 (2002), pp. 364-370
[33.]
G.W. Cotter, R.J. Baglan, T.H. Wasserman, W. Mill.
Palliative radiation treatment of cutaneous mycosis fungoides-a dose response.
Int J Radiat Oncol Biol Phys, 9 (1983), pp. 1477-1480
[34.]
E.A. Olsen, P.A. Bunn.
Interferon in the treatment of cutaneous T-cell lymphoma.
Hematol Oncol Clin North Am, 9 (1995), pp. 1089-1107
[35.]
O. Jumbou, J.M. N’guyen, M.H. Tessier, B. Legoux, B. Dréno.
Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa.
Br J Dermatol, 140 (1999), pp. 427-431
[36.]
E.A. Olsen.
Interferon in the treatment of cutaneous T-cell lymphoma.
Dermatol Ther, 16 (2003), pp. 311-321
[37.]
R. Stadler, H.G. Otte, T. Luger, B.M. Henz, P. Kühl, T. Zwingers, et al.
Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Blood, 92 (1998), pp. 3578-3581
[38.]
C. Zhang, P. Hazarika, X. Ni, D.A. Weidner, M. Duvic.
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Clin Cancer Res, 8 (2002), pp. 1234-1240
[39.]
M.F. Boehm, L. Zhang, B.A. Badea, S.K. White, D.E. Mais, E. Berger, et al.
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
J Med Chem, 37 (1994), pp. 2930-2941
[40.]
M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, C.A. Crowley, Worldwide Bexarotene Study Group, et al.
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Arch Dermatol, 137 (2001), pp. 581-593
[41.]
M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, P. Myskowski, Bexarotene Worldwide Study Group, et al.
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
J Clin Oncol, 19 (2001), pp. 2456-2471
[42.]
C. Assaf, M. Bagot, R. Dummer, M. Duvic, R. Gniadecki, R. Knobler, et al.
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Br J Dermatol, 155 (2006), pp. 261-266
[43.]
F. Foss.
Clinical experience with denileukin diftitox (ONTAK).
Semin Oncol, 33 (2006), pp. 21-25
[44.]
R.J. Kreitman.
Recombinant toxins for the treatment of cancer.
Curr Opin Mol Ther, 5 (2003), pp. 44-51
[45.]
E. Olsen, M. Duvic, A. Frankel, Y. Kim, A. Martin, E. Vonderheid, et al.
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
J Clin Oncol, 19 (2001), pp. 376-388
[46.]
A. Negro-Vilar, Z. Dziewanowska, E.S. Groves, V. Stevens, J.K. Zhang, M. Prince, et al.
Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL).
J Clin Oncol, 25 (2007), pp. 8026
[47.]
D. Greiner, E.A. Olsen, G. Petroni.
Pentostatin (2’-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.
J Am Acad Dermatol, 36 (1997), pp. 950-955
[48.]
E.A. Coors, P. von den Driesch.
Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy.
Br J Dermatol, 143 (2000), pp. 127-131
[49.]
G. Akpek, H.K. Koh, S. Bogen, C. O’Hara, F.M. Foss.
Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Cancer, 86 (1999), pp. 1368-1376
[50.]
A.A. Gabizon.
Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
Cancer Res, 52 (1992), pp. 891-896
[51.]
U. Wollina, R. Dummer, N.H. Brockmeyer, H. Konrad, J.O. Busch, M. Kaatz, et al.
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
Cancer, 98 (2003), pp. 993-1001
[52.]
S. Pulini, S. Rupoli, G. Goteri, N. Pimpinelli, R. Alterini, A. Tassetti, et al.
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Haematologica, 92 (2007), pp. 686-689
[53.]
C. Dumontet, F. Morschhauser, P. Solal-Celigny, F. Bouafia, E. Bourgeois, C. Thieblemont, et al.
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hogkin's lymphoma.
Br J Haematol, 113 (2001), pp. 772-778
[54.]
E. Marchi, L. Alinari, M. Tani, V. Stefoni, N. Pimpinelli, E. Berti, et al.
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Cancer, 104 (2005), pp. 2437-2441
[55.]
I.S. Kazmers, B.S. Mitchell, P.E. DaDonna, L.L. Wotring, L.B. Townsend, W.N. Kelley.
Inhibition of purine nucleoside phosphorylase by 8-aminoguanosin: selective toxicity for T-lymphocytes.
Science, 214 (1981), pp. 1137-1139
[56.]
S. Bantia, P.J. Miller, C.D. Parker, S.L. Ananth, L.L. Horn, J.M. Kilpatrick, et al.
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) – a novel potent and orally active immunosuppressive agent.
Int Immunopharmacol, 1 (2001), pp. 1199-1210
[57.]
S. Bantia, S.L. Ananth, C.D. Parker, L.L. Horn, R. Upshaw.
Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777.
Int Immunopharmacol, 3 (2003), pp. 879-887
[58.]
M. Duvic, A. Forero-Torres, F. Foss, E. Olsen, Y. Kim.
Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study.
Blood, 110 (2006), pp. 22
[59.]
A. Korycka, J.Z. Blonski, T. Robak.
Forodesine (BCX-1777, Immucillin H)—a new purine nucleoside analogue: mechanism of action and potential clinical application.
Mini Rev Med Chem, 7 (2007), pp. 976-983
[60.]
L.S. Villadsen, L. Skov, T.N. Dam, F. Dagnaes-Hansen, J. Rygaard, J. Schuurman, et al.
In situ depletion of CD4(+) T cells in human skin by Zanolimumab.
Arch Dermatol Res, 298 (2007), pp. 449-455
[61.]
S. Marschner, T. Hunig, J.C. Cambier, T.H. Finkel.
Ligation of human CD4 interferes with antigen-induced activation of primary T-cells.
Immunol Lett, 82 (2002), pp. 131-139
[62.]
Y.H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, et al.
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Blood, 109 (2007), pp. 4655-4662
[63.]
C. Assaf, W. Sterry.
Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
Curr Opin Mol Ther, 9 (2007), pp. 197-203
[64.]
M. Duvic, Y. Kim, N.J. Korman, B. Boh, A. Lerner, M.P. Heffernan, et al.
Zanolimumab, a fully human monoclonal antibody: Early results of an ongoing clinical trial in patients with CD4+ mycosis fungoides (MF) type CTCL (stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy.
Blood, 108 (2006), pp. 2731
[65.]
D.S. Mestel, M. Beyer, M. Möbs, M. Steinhoff, W. Sterry, C. Assaf.
Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
Expert Opin Biol Ther, 8 (2008), pp. 1929-1939
[66.]
C.E. Dearden, E. Matutes, D. Catovsky.
Alemtuzumab in T-cell malignancies.
Med Oncol, 19 (2002), pp. 27-32
[67.]
W. Rowan, J. Tite, P. Topley, S.J. Brett.
Cross-linking of the CAMPATH-1 antigen (CD-52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Immunology, 95 (1998), pp. 427-436
[68.]
J. Lundin, A. Osterborg, G. Brittinger, D. Crowther, H. Dombret, A. Engert, et al.
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
J Clin Oncol, 16 (1998), pp. 3257-3263
[69.]
J. Lundin, H. Hagberg, J.R. Repp, E. Cavallin-Stahl, S. Fredén, G. Juliusson, et al.
Phase II Study of Alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome.
Blood, 101 (2003), pp. 4267-4272
[70.]
M.G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, et al.
Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
Haematologica, 92 (2007), pp. 784-794
[71.]
G.A. Kennedy, J.F. Seymour, M. Wolf, H. Januszewicz, J. Davison, C. McCormack, et al.
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Eur J Haematol, 71 (2003), pp. 250-256
[72.]
D.J. Lenihan, A.J. Alencar, D. Yang, R. Kurzrock, M.J. Keating, M. Duvic.
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Blood, 104 (2004), pp. 655-658
[73.]
J. Lundin, B. Kennedy, C. Dearden, M.J. Dyer, A. Osterborg.
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Blood, 105 (2005), pp. 4148-4149
[74.]
J.E. Bolden, M.J. Peart, R.W. Johnstone.
Anticancer activities of histone deacetylase inhibitors.
Nat Rev Drug Discov, 5 (2006), pp. 769-784
[75.]
S. Timmermann, H. Lehrmann, A. Polesskaya, A. Harel-Bellan.
Histone acetylation and disease.
Cell Mol Life Sci, 58 (2001), pp. 728-736
[76.]
W.K. Rasheed, R.W. Johnstone, H.M. Prince.
Histone deacetylase inhibitors in cancer therapy.
Expert Opin Investig Drugs, 16 (2007), pp. 659-678
[77.]
D. Marchion, P. Münster.
Development of histone deacetylase inhibitors for cancer treatment.
Expert Rev Anticancer Ther, 7 (2007), pp. 583-598
[78.]
J.L. Marshall, N. Rizvi, J. Kauh, W. Dahut, M. Figuera, M.H. Kang, et al.
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
J Exp Ther Oncol, 2 (2002), pp. 325-332
[79.]
E.L. Strevel, D.J. Ing, L.L. Siu.
Molecularly targeted oncology therapeutics and prolongation of the QT interval.
J Clin Oncol, 25 (2007), pp. 3362-3371
[80.]
W.K. Kelly, O.A. O’Connor, L.M. Krug, J.H. Chiao, M. Heaney, T. Curley, et al.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
J Clin Oncol, 23 (2005), pp. 3923-3931
[81.]
L.M. Butler, D.B. Agus, H.I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, et al.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Cancer Res, 60 (2000), pp. 5165-5170
[82.]
S. Sakajiri, T. Kumagai, N. Kawamata, T. Saitoh, J.W. Said, H.P. Koeffler.
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Exp Hematol, 33 (2005), pp. 53-61
[83.]
C. Zhang, V. Richon, X. Ni, T. Saitoh, J.W. Said, H.P. Koeffler.
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
J Invest Dermatol, 125 (2005), pp. 1045-1052
[84.]
E.A. Olsen, Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, S. Parker, et al.
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
J Clin Oncol, 25 (2007), pp. 3109-3115
[85.]
M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, et al.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Blood, 109 (2007), pp. 31-39
[86.]
P.A. Konstantinopoulos, G.P. Vandoros, A.G. Papavassiliou.
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Cancer Chemother Pharmacol, 58 (2006), pp. 711-715
[87.]
P.A. Bunn Jr, F.M. Foss.
T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
J Cell Biochem Suppl, 24 (1996), pp. 12-23
[88.]
R.L. Piekarz, R. Robey, V. Sandor, S. Bakke, W.H. Wilson, L. Dahmoush, et al.
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
Blood, 98 (2001), pp. 2865-2868
[89.]
R. Piekarz, R. Frye, J. Wright, W. Figg, S. Allen, M. Kirschbaum, et al.
Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma.
J Clin Oncol, 25 (2007), pp. 8027
[90.]
M. Prince, D. George, R. Johnstone, C. McCormack, L. Ellis, R. Williams-Truax, et al.
LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin expression profiles in the first 24 h related to clinical response following therapy.
Blood, 108 (2006), pp. 2715
[91.]
T. Fisher, A. Patnaik, K. Bhalla, J. Beck, J. Morganroth, G.H. Laird, et al.
Results of cardiac monitoring during phase I trials of a novel histone deacetylase inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies.
J Clin Oncol, 23 (2005), pp. 3106
[92.]
L. Zhang, D. Lebwohl, E. Masson, G. Laird, M.R. Cooper, H.M. Prince.
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
J Clin Oncol, 26 (2008), pp. 332-333
[93.]
R. Advani, K. Hymes, B. Pohlman, E. Jacobsen, J. McDonnell, R. Belt, et al.
Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study.
Blood, 110 (2007), pp. 3453
[94.]
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, K.C. Anderson.
Proteasome inhibitor therapy in multiple myeloma.
Mol Cancer Ther, 4 (2005), pp. 686-692
[95.]
A. Sors, F. Jean-Louis, E. Bégué, L. Parmentier, L. Dubertret, M. Dreano, et al.
Inhibition of I{kappa}B Kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-{kappa}B constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Clin Cancer Res, 14 (2008), pp. 901-911
[96.]
P.L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, M. Fina, et al.
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
J Clin Oncol, 25 (2007), pp. 4293-4297
[97.]
D.A. Pichardo, C. Querfeld, J. Guitart, T.M. Kuzel, S.T. Rosen.
Cutaneous T-cell lymphoma: a paradigm for biological therapies.
Leuk Lymphoma, 45 (2004), pp. 1755-1765
[98.]
R.F. Duarte, N. Schmitz, O. Servitje, A. Sureda.
Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma.
Bone Marrow Transplant, 41 (2008), pp. 597-604
[99.]
R.K. Burt, J. Guitart, A. Traynor, C. Link, S. Rosen, T. Pandolfino, et al.
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graftversus-tumor effect.
Bone Marrow Transplant, 25 (2000), pp. 111-113
[100.]
M.C. Koeppel, A.M. Stoppa, M. Resbeut, D. Blaise, M. Coignet, L. Coulier, et al.
Mycosis fungoides and allogenic bone marrow transplantation.
Acta Derm Venereol, 74 (1994), pp. 331-332
[101.]
K. Kahata, S. Hashino, M. Takahata, F. Fujisawa, T. Kondo, S. Kobayashi, et al.
Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning.
Acta Haematol, 120 (2008), pp. 14-18
[102.]
J.B. Yu, J.M. McNiff, M.W. Lund, L.D. Wilson.
Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy.
Int J Radiat Oncol Biol Phys, 70 (2008), pp. 1542-1545
[103.]
M.W. Bekkenk, F.A. Geelen, P.C. van Voorst Vader, F. Heule, M.L. Geerts, W.A. van Vloten, et al.
Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
Blood, 95 (2000), pp. 3653-3661
[104.]
E.C. Vonderheid, A. Sajjadian, M.E. Kadin.
Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
J Am Acad Dermatol, 34 (1996), pp. 470-481
[105.]
M. Rodrigues, C. McCormack, L.M. Yap, H.M. Prince, H. Roberts, R. Williams, et al.
Successful treatment of lymphomatoid papulosis with photodynamic therapy.
Australas J Dermatol, 50 (2009), pp. 129-132
[106.]
A.F. Wahl, K. Klussman, J.D. Thompson, J.H. Chen, L.V. Francisco, G. Risdon, et al.
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Cancer Res, 62 (2002), pp. 3736-3742
[107.]
Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 (In press).
[108.]
M. Duvic, Y. Kim, S. Reddy, A. Forero-Torres, L.C. Pinter-Brown, M.U. Rarick, et al.
Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+ lymphoproliferative disorders.
Blood, 108 (2006), pp. 2733
[109.]
R. Piccinno, M. Caccialanza, E. Berti, L. Baldini.
Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases.
Int J Radiat Oncol Biol Phys, 27 (1993), pp. 385-389
[110.]
R. Piccinno, M. Caccialanza, E. Berti.
Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma.
Eur J Dermatol, 13 (2003), pp. 49-52
[111.]
N.J. Senff, J.J. Hoefnagel, K.J. Neelis, M.H. Vermeer, E.M. Noordijk, R. Willemze.
Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
Arch Dermatol, 143 (2007), pp. 1520-1526
[112.]
N.J. Senff, E.M. Noordijk, Y.H. Kim, M. Bagot, E. Berti, L. Cerroni, et al.
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
Blood, 112 (2008), pp. 1600-1609
[113.]
A. Cozzio, W. Kempf, R. Schmid-Meyer, M. Gilliet, S. Michaelis, L. Schärer, et al.
Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma.
Leuk Lymphoma, 47 (2006), pp. 865-869
[114.]
B. Kütting, G. Bonsmann, D. Metze, T.A. Luger, L. Cerroni.
Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a.
J Am Acad Dermatol, 36 (1997), pp. 311-314
[115.]
A. Parodi, C. Micalizzi, A. Rebora.
Intralesional natural interferon alpha in the treatment of Crosti's lymphoma (primary cutaneous B follicular centre-cell lymphoma): report of four cases.
J Dermatol Treatment, 7 (1996), pp. 105-107
[116.]
P. Rubegni, G. De Aloe, E. Pianigiani, S. Lazzi, M. Fimiani.
Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A.
J Eur Acad Dermatol Venereol, 12 (1999), pp. 70-71
[117.]
T. Zenone, G. Catimel, N. Barbet, M. Clavel.
Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a.
Eur J Cancer, 30 (1994), pp. 246-247
[118.]
M.R. Smith.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Oncogene, 22 (2003), pp. 7359-7368
[119.]
E. Kimby.
Tolerability and safety of rituximab (MabThera).
Cancer Treat Rev, 31 (2005), pp. 456-473
[120.]
A.V. Morales, R. Advani, S.M. Horwitz, N. Riaz, S. Reddy, R.T. Hoppe, et al.
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
J Am Acad Dermatol, 59 (2008), pp. 953-957
[121.]
S. Gellrich, J.M. Muche, A. Wilks, K.C. Jasch, C. Voit, T. Fischer, et al.
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas–an applicational observation.
Br J Dermatol, 153 (2005), pp. 167-173
[122.]
L. Heinzerling, R. Dummer, W. Kempf, M.H. Schmid, G. Burg.
Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Arch Dermatol, 136 (2000), pp. 374-378
[123.]
K. Kerl, C. Prins, J.H. Saurat, L.E. French.
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Br J Dermatol, 155 (2006), pp. 1197-1200
[124.]
F. Grange, M. Beylot-Barry, P. Courville, E. Maubec, M. Bagot, B. Vergier, et al.
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Arch Dermatol, 143 (2007), pp. 1144-1150
[125.]
N. Mounier, J. Briere, C. Gisselbrecht, J.F. Emile, P. Lederlin, C. Sebban, et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Blood, 101 (2003), pp. 4279-4284
[126.]
B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, et al.
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med, 346 (2002), pp. 235-242
[127.]
P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Fermé, et al.
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Étude des Lymphomes de l’Adulte.
J Clin Oncol, 23 (2005), pp. 4117-4126
[128.]
C. Nourigat, C.C. Badger, I.D. Bernstein.
Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen.
J Natl Cancer Inst, 82 (1990), pp. 47-50
[129.]
S. Maza, S. Gellrich, C. Assaf, M. Beyer, L. Spilker, H. Orawa, et al.
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study.
Leuk Lymphoma, 49 (2008), pp. 1702-1709
[130.]
R.L. Piekarz, R.W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A.H. Abdeldaim, et al.
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Blood, 103 (2004), pp. 4636-4643
[131.]
M.F. Demierre, S. Gan, J. Jones, D.R. Miller.
Significant impact of cutaneous T-cell lymphoma on patients’ quality of life.
Cancer, 107 (2006), pp. 2504-2511
Copyright © 2009. Academia Española de Dermatología y Venereología
